Prothrombin fragment 1 + 2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction

Thrombosis Research

Volumn 124, Issue 5, 2009, Pages 526-530

  Henareh, Loghman ^a   Jogestrand, Tomas ^a   Agewall, Stefan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

atherosclerosis; Coagulation; fibrinolysis; Plasminogen activator inhibitor type 1

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; PROTHROMBIN FRAGMENT 1 PLUS 2; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; B SCAN; BLOOD CLOTTING; BLOOD SAMPLING; CARDIAC PATIENT; COMMON CAROTID ARTERY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPENDENT VARIABLE; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; INDEPENDENT VARIABLE; INTIMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CAROTID ARTERY, COMMON; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; RISK FACTORS; TUNICA MEDIA; VON WILLEBRAND FACTOR;

EID: 70349866247     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.03.014     Document Type: Article

References (46)

1. Fuster V., Badimon L., Badimon J.J., and Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326 (1992) 242-250
2. Fuster V., Stein B., Ambrose J.A., Badimon L., Badimon J.J., and Chesebro J.H. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 82 (1990) 47-59
3. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarti R.R., North W.R., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2 (1986) 533-537
4. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., and van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332 (1995) 635-641
5. Hamsten A., Wiman B., de Faire U., and Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313 (1985) 1557-1563
6. Aznar J., Estelles A., Tormo G., Sapena P., Tormo V., Blanch S., et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 59 (1988) 535-541
7. Kienast J., Thompson S.G., Raskino C., Pelzer H., Fechtrup C., Ostermann H., et al. Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 70 (1993) 550-553
8. Agewall S., Wikstrand J., Suurkula M., Tengborn L., and Fagerberg B. Carotid artery wall morphology, haemostatic factors and cardiovascular disease. An ultrasound study in men at high and low risk for atherosclerotic disease. Blood Coagul Fibrinolysis 5 (1994) 895-904
9. Agewall S., Wikstrand J., Wendelhag I., Tengborn L., and Fagerberg B. Femoral artery wall morphology, hemostatic factors and intermittent claudication: ultrasound study in men at high and low risk for atherosclerotic disease. Haemostasis 26 (1996) 45-57
10. Newby D.E., McLeod A.L., Uren N.G., Flint L., Ludlam C.A., Webb D.J., et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 103 (2001) 1936-1941
11. Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2 (1987) 3-9
12. Huber K., Rosc D., Resch I., Schuster E., Glogar D.H., Kaindl F., et al. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost 60 (1988) 372-376
13. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 14 (1993) 8-17
14. van der Meer I.M., Bots M.L., Hofman A., del Sol A.I., van der Kuip D.A., and Witteman J.C. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 109 (2004) 1089-1094
15. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., and Wolfson Jr. S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 (1999) 14-22
16. Chambless L.E., Folsom A.R., Clegg L.X., Sharrett A.R., Shahar E., Nieto F.J., et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 151 (2000) 478-487
17. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., and Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96 (1997) 1102-1108
18. Folsom A.R., Aleksic N., Park E., Salomaa V., Juneja H., and Wu K.K. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 21 (2001) 611-617
19. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
20. Chenillot O., Henny J., Steinmetz J., Herbeth B., Wagner C., and Siest G. High sensitivity C-reactive protein: biological variations and reference limits. Clin Chem Lab Med 38 (2000) 1003-1011
21. Wendelhag I., Liang Q., Gustavsson T., and Wikstrand J. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke 28 (1997) 2195-2200
22. Lemne C., Jogestrand T., and de Faire U. Carotid intima-media thickness and plaque in borderline hypertension. Stroke 26 (1995) 34-39
23. Nowak J., Nilsson T., Sylven C., and Jogestrand T. Potential of carotid ultrasonography in the diagnosis of coronary artery disease: a comparison with exercise test and variance ECG. Stroke 29 (1998) 439-446
24. Agewall S., Wikstrand J., and Fagerberg B. Prothrombin fragment 1 + 2 is a risk factor for myocardial infarction in treated hypertensive men. J Hypertens 16 (1998) 537-541
25. Paramo J.A., Orbe J., Beloqui O., Benito A., Colina I., Martinez-Vila E., et al. Prothrombin fragment 1 + 2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke 35 (2004) 1085-1089
26. Mann J., and Davies M.J. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 82 (1999) 265-268
27. Davies M.J. The pathophysiology of acute coronary syndromes. Heart 83 (2000) 361-366
28. De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care 3 (2000) 453-467
29. Kawano H., Do Y.S., Kawano Y., Starnes V., Barr M., Law R.E., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101 (2000) 1130-1137
30. Vaughan D.E., Rouleau J.L., Ridker P.M., Arnold J.M., Menapace F.J., and Pfeffer M.A. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 96 (1997) 442-447
31. Qu H.Y., Xiao Y.W., Jiang G.H., Wang Z.Y., Zhang Y., and Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 26 (2009) 958-964
32. Salomaa V., Stinson V., Kark J.D., Folsom A.R., Davis C.E., and Wu K.K. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 91 (1995) 284-290
33. Sakata T., Mannami T., Baba S., Kokubo Y., Kario K., Okamoto A., et al. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Atherosclerosis 176 (2004) 355-360
34. Furumoto T., Fujii S., Nishihara K., Yamada S., Komuro K., Goto K., et al. Maladaptive arterial remodeling with systemic hypertension associated with increased concentrations in blood of plasminogen activator inhibitor type-1 (PAI-1). Am J Cardiol 93 (2004) 997-1001
35. DeYoung M.B., Tom C., and Dichek D.A. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation 104 (2001) 1972-1971
36. Otsuka G., Agah R., Frutkin A.D., Wight T.N., and Dichek D.A. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol 26 (2006) 737-743
37. Czekay R.P., Aertgeerts K., Curriden S.A., and Loskutoff D.J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160 (2003) 781-791
38. Lijnen H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86 (2001) 324-333
39. Zhu Y., Farrehi P.M., and Fay W.P. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation 103 (2001) 3105-3110
40. Carmeliet P., Moons L., Lijnen R., Janssens S., Lupu F., Collen D., et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 96 (1997) 3180-3191
41. de Waard V., Arkenbout E.K., Carmeliet P., Lindner V., and Pannekoek H. Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol 22 (2002) 1978-1983
42. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 340 (1999) 115-126
43. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., and Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349 (1997) 462-466
44. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98 (1998) 839-844
45. Lerman A., and Burnett Jr. J.C. Intact and altered endothelium in regulation of vasomotion. Circulation 86 (1992) 12-19
46. Anderson T.J. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 34 (1999) 631-638